Skip to main content

Table 2 Internationally approved stem cell drugs

From: Principles for establishment of the stem cell bank and its applications on management of sports injuries

Year Corporation Stem cell type Clinical application Name of bank
2009.12 Prochymal/Osiris Therapeutics, Inc., USA Mesenchymal stem cells from human allogeneic bone marrow Graft versus host disease (GVHD) and Crohn’s disease American Food and Drug Administration (FDA)
2010.07 MPC/Mesoblast Autologous mesenchymal precursor cells Bone reconstruction Production permit of Therapeutic Goods Administration (TGA) in Australia
2011.07 Hearticellgram-AMI/FCB-Pharmicell Autologous bone marrow mesenchymal stem cells Acute myocardial infarction Food and Drug Administration in South Korea
2011.11 Hemacord/New York Blood Center Cord blood hematopoietic progenitor cells Hereditary or acquired hematopoietic disease Biological License of American Food and Drug Administration (FDA)
2011.11 MultiStem/Athersys Inc., USA Allogeneic bone marrow stem cell Type I mucopolysaccharidosis American Food and Drug Administration (FDA)
2012.01 Cartistem/Medi-post Mesenchymal stem cells from the cord blood Degenerative arthritis and cartilage damage in the knee joint Food and Drug Administration in South Korea
2012.01 Cuepistem/Anterogen Mesenchymal stem cells from autologous fat Crohn’s disease complicating anal fistula Food and Drug Administration in South Korea